中轴型脊柱关节炎患者影像学进展有限且MRI炎症持续减轻:RAPID-axSpA III期随机试验的4年影像学结果
RAPID-axSpA试验报告了接受 certolizumab pegol(CZP)治疗的中轴型脊柱关节炎患者4年影像学结局。患者随机分组后分别按安慰剂对照、剂量盲法和开放标签阶段随访至第204周。脊柱和骶髂关节MRI炎症从基线至第12周的改善维持至第204周,4年脊柱放射学进展总体较低。
要点
- MRI炎症从基线至第12周改善并维持至第204周。
- AS患者第204周SPARCC缓解率66.7%,nr-axSpA为69.6%。
- AS患者第204周Berlin缓解率65.4%,nr-axSpA为57.3%。
核心结论
- 在接受CZP治疗的中轴型脊柱关节炎患者中,脊柱和骶髂关节MRI炎症的快速下降维持至第204周。
- 4年脊柱放射学进展总体较低,第2至4年的进展低于第0至2年。
- 骶髂关节放射学分级变化显示进展有限。
研究设计与样本
- RAPID-axSpA(NCT01087762)为III期随机试验,第24周前为安慰剂对照双盲,第48周前为剂量盲法,至第204周为开放标签。
- 纳入符合ASAS中轴型脊柱关节炎标准且疾病活动的患者,随机化时根据改良纽约(mNY)标准分层为AS和nr-axSpA。
- 脊柱X线采用改良Stoke强直性脊柱炎脊柱评分(mSASSS)评估。
- MRI炎症采用加拿大脊柱关节炎研究联盟(SPARCC)骶髂关节评分和Berlin脊柱评分评估,缓解分别定义为SPARCC<2和Berlin≤2。
主要发现
- MRI从基线至第12周的改善维持至第204周:SPARCC基线AS=8.5、nr-axSpA=7.5,第204周AS=1.3、nr-axSpA=2.4。
- Berlin评分基线AS=7.4、nr-axSpA=4.4,第204周AS=2.6、nr-axSpA=1.9。
- 基线SPARCC≥2的患者中,第204周达到缓解者AS为66.7%、nr-axSpA为69.6%;基线Berlin>2的患者中,第204周达到缓解者AS为65.4%、nr-axSpA为57.3%。
- AS患者mSASSS从基线至第204周平均变化为0.98(95%CI 0.34,1.63),从基线至第96周为0.67(95%CI 0.21,1.13),从第96周至第204周为0.31(95%CI 0.02,0.60)。
- nr-axSpA患者相应mSASSS变化分别为0.06(95%CI -0.17,0.28)、-0.01(95%CI -0.19,0.17)和0.07(95%CI -0.07,0.20)。
关键数值与推荐
- MRI缓解定义:SPARCC<2和Berlin≤2。
- AS患者基线至第204周mSASSS平均变化0.98(95%CI 0.34,1.63)。
- nr-axSpA患者基线至第204周mSASSS平均变化0.06(95%CI -0.17,0.28)。
临床怎么用
- 原文未据此给出推荐。
局限性
- 原文未报告局限性。
以上解读依据论文摘要(全文未开放获取或许可不允许翻译转载)。
原文
OBJECTIVES: To report 4-year imaging outcomes in the RAPID-axSpA (NCT01087762) study of patients with ankylosing spondylitis (AS) and non-radiographic axial spondyloarthritis (nr-axSpA), treated with certolizumab pegol (CZP). METHODS: This phase III, randomised trial was placebo-controlled and double-blind to week 24, dose-blind to week 48 and open-label to week 204. Patients fulfilling the Assessment of Spondyloarthritis International Society (ASAS) axSpA criteria with active disease were stratified (AS/nr-axSpA) according to the modified New York (mNY) criteria at randomisation. Spinal radiographs were assessed using the modified Stoke Ankylosing Spondylitis Spine Score (mSASSS). MRI inflammation used the Spondyloarthritis Research Consortium of Canada (SPARCC) score for sacroiliac joints (SIJ) and the Berlin spinal score (remission defined as SPARCC <2 and Berlin ≤2, respectively). RESULTS: MRI improvements from baseline (BL) to week 12 were maintained to week 204 (SPARCC BL: AS=8.5, nr-axSpA=7.5; SPARCC week 204: AS=1.3, nr-axSpA=2.4; Berlin BL: AS=7.4, nr-axSpA=4.4; Berlin week 204: AS=2.6, nr-axSpA=1.9). 66.7% of patients with AS and 69.6% of patients with nr-axSpA with BL SPARCC scores ≥2, and 65.4% of patients with AS and 57.3% of patients with nr-axSpA with BL Berlin score >2, achieved remission at week 204. Mean mSASSS change in AS from BL to week 204 was 0.98 (95% CI 0.34, 1.63); 0.67 (95% CI 0.21,1.13) from BL to week 96; and 0.31 (95% CI 0.02,0.60) from week 96 to week 204. Corresponding nr-axSpA changes were 0.06 (95% CI -0.17,0.28), -0.01 (95% CI -0.19,0.17) and 0.07 (95% CI -0.07,0.20). 4.5% of patients with nr-axSpA fulfilled the mNY criteria at week 204, while 4.3% of patients with AS no longer did so. CONCLUSIONS: In patients with CZP-treated axSpA, rapid decreases in spinal and SIJ MRI inflammation were maintained to week 204. Overall, 4-year spinal progression was low, with less progression during years 2-4 than 0-2. Radiographic SIJ grading changes demonstrated limited progression. TRIAL REGISTRATION NUMBER: NCT01087762; Post-results.
引用
- van der Heijde D, Baraliakos X, Hermann KA, et al. Limited radiographic progression and sustained reductions in MRI inflammation in patients with axial spondyloarthritis: 4-year imaging outcomes from the RAPID-axSpA phase III randomised trial. Ann Rheum Dis. 2018. PMID: 29343510. doi:10.1136/annrheumdis-2017-212377
供执业医师工作参考,不替代临床判断;数值与分级以指南原文为准。